{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:08:05Z","timestamp":1781204885511,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK119254"],"award-info":[{"award-number":["R01DK119254"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biomed Eng"],"DOI":"10.1038\/s41551-020-0555-4","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T16:05:02Z","timestamp":1589213102000},"page":"507-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs"],"prefix":"10.1038","volume":"4","author":[{"given":"Caitlin L.","family":"Maikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton A. A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3451-3694","authenticated-orcid":false,"given":"Gillie A.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-3027","authenticated-orcid":false,"given":"Emily C.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8665-9687","authenticated-orcid":false,"given":"Lyndsay M.","family":"Stapleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam W.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8230-4945","authenticated-orcid":false,"given":"Santiago","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0471-1825","authenticated-orcid":false,"given":"Abigail K.","family":"Grosskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-7291","authenticated-orcid":false,"given":"Celine S.","family":"Liong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-8058","authenticated-orcid":false,"given":"Catherine M.","family":"Meis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Troxell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Maahs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Buckingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2301-7126","authenticated-orcid":false,"given":"Eric A.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"555_CR1","unstructured":"Diabetes: Key Facts (World Health Organization, 2017)."},{"key":"555_CR2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-2007-978777","volume":"31","author":"AK Borm","year":"1999","unstructured":"Borm, A. K. et al. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm. Metab. Res. 31, 472\u2013475 (1999).","journal-title":"Horm. Metab. Res."},{"key":"555_CR3","first-page":"A109","volume":"49","author":"A Gottlieb","year":"2000","unstructured":"Gottlieb, A. et al. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks. Diabetes 49, A109 (2000).","journal-title":"Diabetes"},{"key":"555_CR4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.clinthera.2005.10.009","volume":"27","author":"GJ Ryan","year":"2005","unstructured":"Ryan, G. J., Jobe, L. J. & Martin, R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin. Ther. 27, 1500\u20131512 (2005).","journal-title":"Clin. Ther."},{"key":"555_CR5","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","volume":"29","author":"S Edelman","year":"2006","unstructured":"Edelman, S. et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29, 2189\u20132195 (2006).","journal-title":"Diabetes Care"},{"key":"555_CR6","first-page":"1831","volume":"75","author":"MC Jones","year":"2007","unstructured":"Jones, M. C. Therapies for diabetes: pramlintide and exenatide. Am. Fam. Physician 75, 1831\u20131835 (2007).","journal-title":"Am. Fam. Physician"},{"key":"555_CR7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1203\/PDR.0b013e318159af8c","volume":"62","author":"LM Rodriguez","year":"2007","unstructured":"Rodriguez, L. M. et al. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes. Pediatr. Res. 62, 746\u2013749 (2007).","journal-title":"Pediatr. Res."},{"key":"555_CR8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/dc12-0330","volume":"35","author":"SA Weinzimer","year":"2012","unstructured":"Weinzimer, S. A. et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 35, 1994\u20131999 (2012).","journal-title":"Diabetes Care"},{"key":"555_CR9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/1753-0407.12034","volume":"5","author":"G Grunberger","year":"2013","unstructured":"Grunberger, G. Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR. J. Diabetes 5, 110\u2013117 (2013).","journal-title":"J. Diabetes"},{"key":"555_CR10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","volume":"67","author":"DL Hay","year":"2015","unstructured":"Hay, D. L. et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacol. Rev. 67, 564\u2013600 (2015).","journal-title":"Pharmacol. Rev."},{"key":"555_CR11","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1021\/bi500592p","volume":"53","author":"H Wang","year":"2014","unstructured":"Wang, H. et al. Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility. Biochemistry 53, 5876\u20135884 (2014).","journal-title":"Biochemistry"},{"key":"555_CR12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2005-837662","volume":"113","author":"R Ratner","year":"2005","unstructured":"Ratner, R. et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp. Clin. Endocrinol. Diabetes 113, 199\u2013204 (2005).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"555_CR13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","volume":"25","author":"F Whitehouse","year":"2002","unstructured":"Whitehouse, F. et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25, 724\u2013730 (2002).","journal-title":"Diabetes Care"},{"key":"555_CR14","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","volume":"21","author":"RE Ratner","year":"2004","unstructured":"Ratner, R. E. et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet. Med. 21, 1204\u20131212 (2004).","journal-title":"Diabet. Med."},{"key":"555_CR15","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/dc13-2289","volume":"37","author":"C Hampp","year":"2014","unstructured":"Hampp, C. et al. Use of antidiabetic drugs in the U.S., 2003\u20132012. Diabetes Care 37, 1367\u20131374 (2014).","journal-title":"Diabetes Care"},{"key":"555_CR16","first-page":"101S","volume":"32","author":"C Martin","year":"2006","unstructured":"Martin, C. The physiology of amylin and insulin: maintaining the balance between glucose secretion and glucose uptake. Diabetes Educ. 32, 101S\u2013104S (2006).","journal-title":"Diabetes Educ."},{"key":"555_CR17","doi-asserted-by":"crossref","first-page":"A110","DOI":"10.2337\/diabetes.54.4.1100","volume":"54","author":"RA Heptulla","year":"2005","unstructured":"Heptulla, R. A. et al. The role of subcutaneous pramlintide infusion in the treatment of adolescents with type 1 diabetes. Diabetes 54, A110\u2013A111 (2005).","journal-title":"Diabetes"},{"key":"555_CR18","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1742-1241.2006.01219.x","volume":"60","author":"LL Want","year":"2006","unstructured":"Want, L. L. & Ratner, R. Exenatide and pramlintide: new therapies for diabetes. Int. J. Clin. Pract. 60, 1522\u20131523 (2006).","journal-title":"Int. J. Clin. Pract."},{"key":"555_CR19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrendo.2017.39","volume":"13","author":"C Mathieu","year":"2017","unstructured":"Mathieu, C. et al. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat. Rev. Endocrinol. 13, 385\u2013399 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"555_CR20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199707173370307","volume":"337","author":"F Holleman","year":"1997","unstructured":"Holleman, F. & Hoekstra, J. B. L. Insulin lispro. N. Engl. J. Med. 337, 176\u2013183 (1997).","journal-title":"N. Engl. J. Med."},{"key":"555_CR21","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-017-2233-0","volume":"34","author":"K Gast","year":"2017","unstructured":"Gast, K. et al. Rapid-acting and human insulins: hexamer dissociation kinetics upon dilution of the pharmaceutical formulation. Pharm. Res. 34, 2270\u20132286 (2017).","journal-title":"Pharm. Res."},{"key":"555_CR22","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/dom.12504","volume":"17","author":"MC Riddle","year":"2015","unstructured":"Riddle, M. C. et al. Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. Diabetes Obes. Metab. 17, 904\u2013907 (2015).","journal-title":"Diabetes Obes. Metab."},{"issue":"Suppl. 1","key":"555_CR23","doi-asserted-by":"crossref","first-page":"210-OR","DOI":"10.2337\/db18-210-OR","volume":"67","author":"A Haidar","year":"2018","unstructured":"Haidar, A. et al. Insulin-plus-pramlintide artificial pancreas in type 1 diabetes\u2014randomized controlled trial. Diabetes 67(Suppl. 1), 210-OR (2018).","journal-title":"Diabetes"},{"key":"555_CR24","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.2337\/dc18-1091","volume":"41","author":"MC Riddle","year":"2018","unstructured":"Riddle, M.C. et al. Control of postprandial hyperglycemia in type 1 diabetes by 24-hour fixed-dose coadministration of pramlintide and regular human insulin: a randomized, two-way crossover study. Diabetes Care 41, 2346\u20132352 (2018).","journal-title":"Diabetes Care"},{"key":"555_CR25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","volume":"27","author":"MC Manning","year":"2010","unstructured":"Manning, M. C. et al. Stability of protein pharmaceuticals: an update. Pharm. Res. 27, 544\u2013575 (2010).","journal-title":"Pharm. Res."},{"key":"555_CR26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","volume":"13","author":"S Mitragotri","year":"2014","unstructured":"Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655\u2013672 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"555_CR27","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/bi101926u","volume":"50","author":"C Yang","year":"2011","unstructured":"Yang, C., Lu, D. & Liu, Z. How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation. Biochemistry 50, 2585\u20132593 (2011).","journal-title":"Biochemistry"},{"key":"555_CR28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1208\/s12249-013-9987-4","volume":"14","author":"LH Guerreiro","year":"2013","unstructured":"Guerreiro, L. H. et al. Preparation and characterization of PEGylated amylin. AAPS PharmSciTech 14, 1083\u20131097 (2013).","journal-title":"AAPS PharmSciTech"},{"key":"555_CR29","doi-asserted-by":"crossref","first-page":"e0138803","DOI":"10.1371\/journal.pone.0138803","volume":"10","author":"T Sisnande","year":"2015","unstructured":"Sisnande, T. et al. Monoconjugation of human amylin with methylpolyethyleneglycol. PLoS ONE 10, e0138803 (2015).","journal-title":"PLoS ONE"},{"key":"555_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese, F. M. & Mero, A. The impact of PEGylation on biological therapies. BioDrugs 22, 315\u2013329 (2008).","journal-title":"BioDrugs"},{"key":"555_CR31","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1073\/pnas.1616639113","volume":"113","author":"MJ Webber","year":"2016","unstructured":"Webber, M. J. et al. Supramolecular PEGylation of biopharmaceuticals. Proc. Natl Acad. Sci. USA 113, 14189\u201314194 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"555_CR32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/acs.molpharmaceut.6b00678","volume":"14","author":"T Hirotsu","year":"2017","unstructured":"Hirotsu, T. et al. Self-assembly PEGylation retaining activity (SPRA) technology via a host\u2013guest interaction surpassing conventional PEGylation methods of proteins. Mol. Pharm. 14, 368\u2013376 (2017).","journal-title":"Mol. Pharm."},{"key":"555_CR33","doi-asserted-by":"crossref","first-page":"14511","DOI":"10.1021\/ja0548440","volume":"127","author":"M Bush","year":"2005","unstructured":"Bush, M., Bouley, N. & Urbach, A. R. Charge-mediated recognition of N-terminal tryptophan in aqueous solution by a synthetic host. J. Am. Chem. Soc. 127, 14511\u201314517 (2005).","journal-title":"J. Am. Chem. Soc."},{"key":"555_CR34","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1021\/ja064323s","volume":"128","author":"LM Heitmann","year":"2006","unstructured":"Heitmann, L. M. et al. Sequence-specific recognition and cooperative dimerization of N-terminal aromatic peptides in aqueous solution by a synthetic host. J. Am. Chem. Soc. 128, 12574\u201312581 (2006).","journal-title":"J. Am. Chem. Soc."},{"key":"555_CR35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10847-008-9464-y","volume":"62","author":"P Rajgariah","year":"2008","unstructured":"Rajgariah, P. & Urbach, A. R. Scope of amino acid recognition by cucurbit[8]uril. J. Incl. Phenom. Macro. 62, 251\u2013254 (2008).","journal-title":"J. Incl. Phenom. Macro."},{"key":"555_CR36","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1021\/ja808936y","volume":"131","author":"JJ Reczek","year":"2009","unstructured":"Reczek, J. J. et al. Multivalent recognition of peptides by modular self-assembled receptors. J. Am. Chem. Soc. 131, 2408\u20132415 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"555_CR37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ijch.201700092","volume":"58","author":"H Yin","year":"2018","unstructured":"Yin, H. & Wang, R. Applications of cucurbit[n]urils (n\u2009=\u20097 or 8) in pharmaceutical sciences and complexation of biomolecules. Isr. J. Chem. 58, 188\u2013198 (2018).","journal-title":"Isr. J. Chem."},{"key":"555_CR38","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ijch.201100033","volume":"51","author":"S Walker","year":"2011","unstructured":"Walker, S. et al. The potential of cucurbit[n]urils in drug delivery. Isr. J. Chem. 51, 616\u2013624 (2011).","journal-title":"Isr. J. Chem."},{"key":"555_CR39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/nyas.13376","volume":"1398","author":"KI Kuok","year":"2017","unstructured":"Kuok, K. I. et al. Cucurbit[7]uril: an emerging candidate for pharmaceutical excipients. Ann. NY Acad. Sci. 1398, 108\u2013119 (2017).","journal-title":"Ann. NY Acad. Sci."},{"key":"555_CR40","unstructured":"Berthon, G. Handbook of Metal\u2013Ligand Interactions in Biological Fluids: Bioinorganic Chemistry (Marcel Dekker, 1995)."},{"key":"555_CR41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1385\/BTER:83:3:207","volume":"83","author":"RS Waters","year":"2001","unstructured":"Waters, R. S. et al. EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol. Trace Elem. Res. 83, 207\u2013221 (2001).","journal-title":"Biol. Trace Elem. Res."},{"key":"555_CR42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0301-4622(91)85023-J","volume":"39","author":"S Hvidt","year":"1991","unstructured":"Hvidt, S. Insulin association in neutral solutions studied by light scattering. Biophys. Chem. 39, 205\u2013213 (1991).","journal-title":"Biophys. Chem."},{"key":"555_CR43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/er.2007-0002","volume":"28","author":"SE Fineberg","year":"2007","unstructured":"Fineberg, S. E. et al. Immunological responses to exogenous insulin. Endocr. Rev. 28, 625\u2013652 (2007).","journal-title":"Endocr. Rev."},{"key":"555_CR44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/193229681200600209","volume":"6","author":"RJ Woods","year":"2012","unstructured":"Woods, R. J. et al. Intrinsic fibrillation of fast-acting insulin analogs. J. Diabetes Sci. Technol. 6, 265\u2013276 (2012).","journal-title":"J. Diabetes Sci. Technol."},{"key":"555_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpc.2016.09.007","volume":"219","author":"DC da Silva","year":"2016","unstructured":"da Silva, D. C. et al. Amyloidogenesis of the amylin analogue pramlintide. Biophys. Chem. 219, 1\u20138 (2016).","journal-title":"Biophys. Chem."},{"key":"555_CR46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.180605","volume":"193","author":"AA Like","year":"1976","unstructured":"Like, A. A. & Rossini, A. A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193, 415\u2013417 (1976).","journal-title":"Science"},{"key":"555_CR47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","volume":"46","author":"BR Gedulin","year":"1997","unstructured":"Gedulin, B. R., Rink, T. J. & Young, A. A. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46, 67\u201370 (1997).","journal-title":"Metabolism"},{"key":"555_CR48","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1007\/s11095-016-2014-1","volume":"33","author":"MP Knadler","year":"2016","unstructured":"Knadler, M. P. et al. Addition of 20-kDa PEG to insulin lispro alters absorption and decreases clearance in animals. Pharm. Res. 33, 2920\u20132929 (2016).","journal-title":"Pharm. Res."},{"key":"555_CR49","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1021\/acsami.8b22151","volume":"11","author":"L Zou","year":"2019","unstructured":"Zou, L., Braegelman, A. S. & Webber, M. J. Dynamic supramolecular hydrogels spanning an unprecedented range of host\u2013guest affinity. ACS Appl. Mater. Interfaces 11, 5695\u20135700 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"555_CR50","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.1021\/ja201581x","volume":"133","author":"JM Chinai","year":"2011","unstructured":"Chinai, J. M. et al. Molecular recognition of insulin by a synthetic receptor. J. Am. Chem. Soc. 133, 8810\u20138813 (2011).","journal-title":"J. Am. Chem. Soc."},{"key":"555_CR51","first-page":"5.47.1","volume":"40","author":"KK Wu","year":"2008","unstructured":"Wu, K. K. & Huan, Y. Streptozotocin-induced diabetic models in mice and rats. Curr. Protoc. Pharmacol. 40, 5.47.1\u20135.47.14 (2008).","journal-title":"Curr. Protoc. Pharmacol."},{"key":"555_CR52","doi-asserted-by":"crossref","first-page":"1900094","DOI":"10.1002\/adtp.201900094","volume":"3","author":"CL Maikawa","year":"2019","unstructured":"Maikawa, C. L. et al. Stable monomeric insulin formulations enabled by supramolecular PEGylation of insulin analogues. Adv. Ther. 3, 1900094 (2019).","journal-title":"Adv. Ther."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-020-0555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-020-0555-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-020-0555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T03:41:53Z","timestamp":1670298113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-020-0555-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1038\/s41551-020-0555-4","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"11 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.A.A., B.A.B., D.M.M., C.L.M. and G.A.R. are inventors on a patent filing (provisional application no. 62\/804,357) describing the work reported in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}